The Epidemiology of Prostate Cancer-with a Focus on Nonsteroidal Anti-inflammatory Drugs

Hematology/Oncology Clinics of North America

Volumn 20, Issue 4, 2006, Pages 797-809

  Chan, June M ^a,b   Feraco, Angela ^a   Shuman, Marc ^c,d   Hernández Díaz, Sonia ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LUMIRACOXIB; MANGANESE SUPEROXIDE DISMUTASE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ROFECOXIB; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; SULINDAC; VALDECOXIB; VASCULOTROPIN;

ADENOMATOUS POLYP; AGE DISTRIBUTION; ALZHEIMER DISEASE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DIETARY INTAKE; DIGESTIVE SYSTEM PERFORATION; DNA MODIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; ENZYME SYNTHESIS; ESOPHAGUS CANCER; EUROPE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LUNG CANCER; META ANALYSIS; MORBIDITY; MULTIVARIATE ANALYSIS; NEUROLOGIC DISEASE; NONHUMAN; OSTEOARTHRITIS; PANCREAS CANCER; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SEX ROLE; STATISTICAL SIGNIFICANCE; STOMACH CANCER; STROKE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 33745991189     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.03.002     Document Type: Review

References (68)

1. Chan J.M., Jou R.M., and Carroll P.R. The relative impact and future burden of prostate cancer in the United States. J Urol 172 5 Pt 2 (2004) S13-S17
2. Brawley O.W. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 80 (1997) 1857-1863
3. Penson DF, Chan JM. Prostate cancer. Urological Diseases of America; in press.
4. Chan J.M., Gann P.H., and Giovannucci E.L. Role of diet in prostate cancer development and progression. J Clin Oncol 23 (2005) 8152-8160
5. Gupta S., Adhami V.M., Subbarayan M., et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64 (2004) 3334-3343
6. Leitzmann M.F., Stampfer M.J., Ma J., et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 11 10 Pt 1 (2002) 1108-1111
7. 2. In: Honn K.V., et al. (Ed). Eicosanoids and other bioactive lipids in cancer inflammation and radiation injury 3 (1997), Plenum Press, New York 163-170
8. Chaudry A.A., Wahle K.W., McClinton S., et al. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 57 (1994) 176-180
9. Hughes-Fulford M., Chen Y., and Tjandrawinata R.R. Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 22 (2001) 701-707
10. Hughes-Fulford M., Tjandrawinata R.R., Li C.F., et al. Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells. Carcinogenesis 26 (2005) 1520-1526
11. Subbaramaiah K., Altorki N., Chung W.J., et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274 (1999) 10911-10915
12. Badawi A.F., Liu Y., Eldeen M.B., et al. Age-associated changes in the expression pattern of cyclooxygenase-2 and related apoptotic markers in the cancer susceptible region of rat prostate. Carcinogenesis 25 (2004) 1681-1688
13. Zha S., Gage W.R., Sauvageot J., et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61 24 (2001) 8617-8623
14. Eibl G., Reber H.A., Wente M.N., et al. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 26 (2003) 33-41
15. Maier T.J., Schilling K., Schmidt R., et al. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67 (2004) 1469-1478
16. Yamaguchi K., Lee S.H., Eling T.E., et al. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J Biol Chem 279 (2004) 49617-49623
17. Mahmud S., Franco E., and Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90 (2004) 93-99
18. Harris R.E., Beebe-Donk J., Doss H., et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 13 (2005) 559-583
19. Pruthi R.S., Derksen J.E., and Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Br J Urol Int 93 (2004) 275-278
20. Eibl G., Takata Y., Boros L.G., et al. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res 65 (2005) 982-990
21. Barrett-Connor E. Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys Lecture. Circulation 95 (1997) 252-264
22. Murray CJ, Lopez AD. Global Health Statistics. Harvard: World Health Organization; 1996. Available at: http://www.hup.harvard.edu/catalog/MURGLH.html?show=contents.
23. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
24. Eidelman R., Hebert P., Weisman S., et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 163 (2003) 2006-2010
25. Hart R.G., Halperin J.L., McBride R., et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 57 (2000) 326-332
26. Hayden M., Pignone M., Phillips C., et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 136 (2002) 161-172
27. Kaufman D.W., Kelly J.P., Rosenberg L., et al. Recent patterns of medication use in the ambulatory adult population of the United States. The Slone Survey. JAMA 287 (2002) 337-344
28. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000) 834-839
29. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310 (1995) 827-830
30. Chan A., Manson J.E., Feskanich D., et al. Long-term aspirin use and mortality among women. [abstract]. Gastroenterology (2006) 130(4)(Suppl 2):A101
31. Patrono C., Bachmann F., Baigent C., et al. Expert consensus document on the use of antiplatelet agents: the Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J 25 (2004) 166-181
32. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
33. Bresalier R., Sandler R., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial investigators. N Engl J Med 352 (2005) 1092-1102
34. Merck announces voluntary worldwide withdrawal of Vioxx. September 30, 2004. Available at: http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp.
35. Curtis S.P., Mukhopadhyay S., Ramey D., et al. Etoricoxib cardiovascular safety summary. Circulation 108 (2003) S1758
36. Farkouh M.E., Kirhner H., Harrington R.A., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364 (2004) 675-684
37. Nussmeier N., Whelton A., Brown M., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
38. Ott E., Nussmeier N., Duke P., et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125 (2003) 1481-1492
39. Solomon S., McMurray J., Pfeffer M., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
40. Pfizer statement on new information regarding cardiovascular safety of Celebrex. December 17, 2004. Available at: www.pfizer.com/are/investors_releases/2004pr/mn_2004_1217.cfm.
41. Hernández-Díaz S., Varas-Lorenzo C., and García-Rodríguez L. Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98 (2006) 266-274
42. Patrono C., Coller B., Dalen J., et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 126 (2004) 234S-264S
43. Gurwitz J., Avorn J., and Bohn R. Initiation of antihypertensive treatment during non-steroidal antiinflammatory drug therapy. JAMA 272 (1994) 781-786
44. Johnson A. NSAIDs and increased blood pressure: what is the clinical significance. Drug Saf 17 (1997) 277-289
45. Fitzgerald G., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 (2001) 433-442
46. Gorelick P.B., and Weisman S.M. Risk of hemorrhagic stroke with aspirin use: an update. Stroke 36 (2005) 1801-1807
47. Hernández-Díaz S., and García Rodríguez L.A. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 55 (2002) 157-163
48. García Rodríguez L.A., Hernández-Díaz S., and De Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 52 (2001) 563-571
49. Hernández-Díaz S., and García-Rodríguez L.A. Overview of epidemiological studies published in the nineties on the association between non-steroidal anti-inflammatory drugs and upper gastrointestinal bleed/perforation. Arch Intern Med 160 (2000) 2093-2099
50. Langman M., Jensen D., Watson D., et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282 (1999) 1929-1933
51. Silverstein F., Faich G., Goldstein J., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study, a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
52. Lugardon S., Lapeyre-Mestre M., and Montastrue J. The French Network of Regional Pharmacovigilance Centres. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur J Clin Pharmacol 60 (2004) 673-677
53. MacDonald T., Morant S., Goldstein J., et al. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 52 (2003) 1265-1270
54. Mamdani M., Rochon P., Juurlink D., et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325 (2002) 624
55. Norgard B., Pedersen L., Johnsen S.P., et al. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Phasmacol Ther 19 (2004) 817-825
56. Rahme E., Bardou M.Y., Dasupta K., et al. Gastrointestinal safety of rofecoxib and celecoxib versus NSAIDs among patients on low dose aspirin. Pharmacoepidemiol Drug Saf 13 (2004) S233-S234
57. Eidelman R.S., Hebert P.R., Weisman S.M., et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 163 (2003) 2006-2010
58. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328 (1993) 1313-1316
59. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
60. Chan A.T., Giovannucci E.L., Meyerhardt J.A., et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294 (2005) 914-923
61. Gonzalez-Perez A., Garcia Rodriguez L.A., and Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3 (2003) 28
62. Anderson K.E., Johnson T.W., Lazovich D., et al. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94 (2002) 1168-1171
63. Schernhammer E.S., Kang J.H., Chan A.T., et al. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96 (2004) 22-28
64. Bynum J.P., Rabins P.V., Weller W., et al. The relationship between a dementia diagnosis, chronic illness, medicare expenditures, and hospital use. J Am Geriatr Soc 52 (2004) 187-194
65. Etminan M., Gill S., and Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327 (2003) 128
66. Aisen P.S., Schafer K.A., Grundman M., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 (2003) 2819-2826
67. Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol 18 (2005) 363-369
68. Chen H., Jacobs E., Schwarzschild M.A., et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58 6 (2005) 963-967